We are the combination of four hospitals: the General Hospital, the Children’s Hospital, the Women’s Hospital and the Traumatology, Rehabilitation and Burns Hospital. We are part of the Vall d’Hebron Barcelona Hospital Campus: a world-leading health park where healthcare plays a crucial role.
Patients are the centre and the core of our system. We are professionals committed to quality care and our organizational structure breaks down the traditional boundaries between departments and professional groups, with an exclusive model of knowledge areas.
Would you like to know what your stay at Vall d'Hebron will be like? Here you will find all the information.
The commitment of Vall d'Hebron University Hospital to innovation allows us to be at the forefront of medicine, providing first class care adapted to the changing needs of each patient.
Dr. Robert Medcalf, NHMRC Principal Research Fellow and Director of the Molecular Neurotrauma and Haemostasis Group, Monash, Melbourne
"Plasminogen activation and stroke: can we predict thrombolysis outcome?"
Robert Medcalf was awarded his Ph.D. from the University of Melbourne in 1984. His first post-doctoral appointment was at the University of Melbourne where he investigated the role of the plasminogen activating system in rheumatoid arthritis. In 1986, he continued his research in Lausanne, Switzerland where he extended his interest in the field of plasminogen activation and fibrinolysis. In 1993, he returned to Australia where he established a laboratory at Monash University in Melbourne. He was appointed as a NHMRC Senior Research Fellow in 2003. He has published more than 90 papers in peer reviewed journals on fibrinolysis and plasminogen activation and has an H-index of 30. Since 2000, his research has attracted more than $7m in peer reviewed funding from the NHMRC, the National Heart Foundation, the Brain Research Foundation and the Victorian Neurotrauma Initiative. He was elected as Chairman of the International Society on Fibrinolysis and Proteolysis (ISFP) in 2004 and in 2008 and he will also be Congress President of the 2019 meeting of the International Society on Thrombosis and Haemostasis (ISTH) in Melbourne. He is Associate Editor of the Journal of Thrombosis and Haemostasis which is the flagship journal of both the ISFP and the ISTH and is on the Editorial Board of the Journal of Biological Chemistry.
Host: Neurovascular Research Group (VHIR) alejandro.bustamante@vhir.org
The acceptance of these terms implies that you give your consent to the processing of your personal data for the provision of the services you request through this portal and, if applicable, to carry out the necessary procedures with the administrations or public entities involved in the processing. You may exercise the mentioned rights by writing to web@vallhebron.cat, clearly indicating in the subject line “Exercise of LOPD rights”. Responsible entity: Vall d’Hebron University Hospital (Catalan Institute of Health). Purpose: Subscription to the Vall d’Hebron Barcelona Hospital Campus newsletter, where you will receive news, activities, and relevant information. Legal basis: Consent of the data subject. Data sharing: If applicable, with VHIR. No other data transfers are foreseen. No international transfer of personal data is foreseen. Rights: Access, rectification, deletion, and data portability, as well as restriction and objection to its processing. The user may revoke their consent at any time. Source: The data subject. Additional information: Additional information can be found at https://hospital.vallhebron.com/es/politica-de-proteccion-de-datos.